enGene Therapeuti…
CACADenGene Therapeutics Inc. (US:ENGN) — Biotechnology: Biological Products (No Diagnostic Substances). Počet burz, na kterých se obchodují akcie společnosti: 1. Na této stránce — cena a graf, dividendy, největší akcionáři a historie počtu akcií.
O společnosti
- Web
- engene.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sídlo
- SAINT-LAURENT, Canada
- Generální ředitel
- Mr. Ronald H. W. Cooper
- Zaměstnanci
- 81
- Akcie v oběhu
- 67.02 mil. k 2026-09-02
- Volně obchodovatelné akcie
- 32.75 mil.
- Tržní kapitalizace
- 132.02 mil. USD
- Insideři
- 0.11%
- Instituce
- 84.11%
- Odvětví (SIC)
- Biological Products, (No Diagnostic Substances)
Popis
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Burzy a tickery
| Burza | Ticker | Měna | Cena | Typ |
|---|---|---|---|---|
| US USA Stocks | ENGN | USD | 1.8 -3.74% | kmenové akcie |
Dividendy
Nebyly nalezeny žádné výplaty dividend (zkontrolováno 07.10.2026). Společnost pravděpodobně nevyplácí dividendy.
Zprávy tento týden
Zatím žádné zprávy z webu společnosti.
Největší držitelé
| Držitel | Podíl | Akcie | Datum zprávy |
|---|---|---|---|
| FCPM III Services B.V. | 14.37% | 9.63 mil. | 2026-06-30 |
| BML Capital Management,… | 9.95% | 6.67 mil. | 2026-06-30 |
| Siren, L.L.C. | 9.34% | 6.26 mil. | 2026-06-30 |
| Perceptive Advisors Llc | 7.2% | 4.82 mil. | 2026-06-30 |
| Ameriprise Financial, In… | 3.99% | 2.68 mil. | 2026-06-30 |
| Nextech Invest, Ltd. | 3.47% | 2.32 mil. | 2026-06-30 |
| Adar1 Capital Management… | 3.14% | 2.1 mil. | 2026-06-30 |
| Vestal Point Capital, LP | 2.49% | 1.67 mil. | 2026-06-30 |
| Acorn Capital Advisors,… | 1.9% | 1.27 mil. | 2026-06-30 |
| Peapod Lane Capital LLC | 1.64% | 1.1 mil. | 2026-06-30 |
| Franklin Strategic Serie… | 0.73% | 486 579 | 2026-04-30 |
| Fidelity Concord Street… | 0.05% | 34 982 | 2026-07-31 |
| ETFis Series Trust I-Vir… | 0.05% | 32 625 | 2026-04-30 |
| TIFF INVESTMENT PROGRAM-… | 0.02% | 10 639 | 2026-06-30 |
| JNL Series Trust-JNL/DFA… | 0.01% | 9 974 | 2026-06-30 |
| Exchange Place Advisors… | 0.01% | 7 649 | 2026-06-30 |
| GROSSMAN WILLIAM (Office… | ≈0.01% | 5 102 | 2026-09-22 |
| Advanced Series Trust-AS… | 0% | 1 376 | 2026-06-30 |
| FORBION GROWTH OPPORTUNI… | — | — | 2024-10-30 |
